Ratings MEI Pharma, Inc. Deutsche Boerse AG

Equities

MMI0

US55279B3015

Delayed Deutsche Boerse AG Other stock markets 02:13:00 2023-04-18 am EDT			5-day change	1st Jan Change
4.2 ^EUR	-17.32%		-.--%	-.--%

May. 09	MEI Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024	CI
Apr. 11	MEI Pharma, Inc. Announces Strategic Plan to Leverage Recent Positive Voruciclib and ME-344 Clinical Data	CI

Summary

Overall, the company has poor fundamentals for a medium to long-term investment strategy.

Strengths

Over the last twelve months, the sales forecast has been frequently revised upwards.
For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
For several months, analysts have been revising their EPS estimates roughly upwards.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Historically, the company has been releasing figures that are above expectations.

Weaknesses

According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
Low profitability weakens the company.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
MEI PHARMA, INC.	-.--%	18.79M	-
MODERNA, INC.	+33.56%	51.07B	B-
IQVIA HOLDINGS INC.	-8.08%	38.78B	B
LONZA GROUP AG	+35.88%	38.61B	A
CELLTRION, INC.	-10.62%	27.32B	C
ICON PUBLIC LIMITED COMPANY	+11.64%	26.35B	B-
ALNYLAM PHARMACEUTICALS, INC.	-18.97%	19.46B	B
UNITED THERAPEUTICS CORPORATION	+40.61%	13.58B	B+
MEDPACE HOLDINGS, INC.	+29.41%	12.46B	C+
BIO-TECHNE CORPORATION	-4.08%	11.75B	B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes